StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Truist Securities Reiterates Buy Rating on Amgen (AMGN)
September 25, 2024 5:43 AM
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $320.00 price target on Amgen (NASDAQ: AMGN).The analyst comments "Earlier ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.20%
September 24, 2024 4:42 PM
Amgen (AMGN) Tepezza Receives Approval In Japan For The Treatment Of Active Thyroid Eye Disease
September 24, 2024 4:00 PM
TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
September 24, 2024 4:00 PM
Regeneron slump continues as analysts turn more cautious
September 24, 2024 12:16 PM
Amgen (AMGN) To Host Conference Call To Discuss New Topline Data In Inflammation And Rare Disease
September 23, 2024 4:01 PM
AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE
September 23, 2024 4:00 PM
